Advanced search
Publication Cover
Modern Rheumatology Volume 30, 2020 - Issue 1
Journal homepage
4,575
Views
34
CrossRef citations to date
0
Altmetric
Original Articles: Rheumatoid Arthritis

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

Masayoshi HarigaiDivision of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Department of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan; View further author information
,
Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; View further author information
,
Josef S. SmolenDivision of Rheumatology, Department of Medicine, Medical University of Vienna, Vienna, Austria; View further author information
,
Kevin L. WinthropDepartment of Medicine & Ophthalmology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Atsushi NishikawaMedicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan; View further author information
,
Terence P. RooneyLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Chadi G. SaifanLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Maher IssaLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Yoshitaka IsakaMedicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan; View further author information
,
Naotsugu AkashiMedicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan; Correspondence[email protected]
View further author information
,
Taeko IshiiMedicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan; View further author information
&
Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanView further author information
 show all
Pages 36-43 | Received 20 Dec 2018, Accepted 25 Jan 2019, Published online: 21 Mar 2019

Related Research Data

Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials
Source: Informa UK Limited
JAKs and STATs in Immunity, Immunodeficiency, and Cancer
Source: Massachusetts Medical Society
BARICITINIB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
Source: Wiley
Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials
Source: Wiley
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
Source: Springer Science and Business Media LLC
Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study.
Source: Oxford University Press (OUP)
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
Source: Centers for Disease Control MMWR Office
Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.
Source: Informa UK Limited
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
Source: Taylor & Francis
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Source: BMJ
Rheumatoid arthritis
Source: Elsevier BV
RISK OF HZ WITH TOFACITINIB AND CONCOMITANT THERAPY
Source: Wiley
International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH).
Source: Wiley
Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Source: Informa UK Limited

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.